Israel’s Medi-Tate Purchased by Olympus for $300 Million – Jewish Enterprise Information

Israel’s Medi-Tate Purchased by Olympus for $300 Million

Medi-Tate gives males non-surgical choices for urinary points.

Olympus, a Japanese medical company, has paid $300 million to amass 100% of Israeli medtech startup Medi-Tate. Olympus made its preliminary funding in Medi-Tate of $20 million in November 2018, beneath an settlement that included the rights to distribute Medi-Tate merchandise. That funding additionally gave Olympus an choice to amass 100% of the Israeli firm at a later date.

Based in 2007 by its CEO Ido Kilemnik, Medi-Tate is an Israeli medical machine firm which works to enhance males’s healthcare and high quality of life through efficient, non-surgical options for Benign Prostatic Hyperplasia (BPH). Its flagship iTind therapy for BPH at present has the EU CE Mark and is accredited on the market within the European Union, UK, Israel, Australia, Brazil, and the FDA cleared to be used in the US.


iTind is a briefly implanted nitinol machine which helps the reduction of LUTS as a result of BPH. The iTind therapy is carried out by a urologist in an outpatient hospital, ambulatory surgical procedure middle or a clinic, the place the machine is positioned within the prostatic urethra in a folded configuration.

The machine slowly expands and exerts light strain at three exact factors to reshape the prostatic urethra and bladder neck. After 5 to seven days, the machine is totally eliminated, leaving a wider opening via which urine can circulate, and to alleviate the signs of BPH.

Ido Kilemnik mentioned in a press release, “We’re happy to be becoming a member of Olympus, which shares our imaginative and prescient of constructing iTind the worldwide customary for BPH therapy. In the present day’s announcement is a testomony to our give attention to long-term scientific outcomes and the arduous work and dedication of the whole Medi-Tate staff. We’re excited to be cooperating with Olympus in our effort to enhance sufferers’ lives.”

“As the present market chief within the BPH surgical procedure subject, Olympus has the best platform to propel iTind onward and guarantee many males have higher entry to this necessary technique of therapy,” mentioned Vanessa Malka, Medi-Tate’s VP of Advertising and marketing and Enterprise Improvement.


Learn extra about: Medi-Tate, Olympus


Israel’s Medi-Tate Bought by Olympus for $300 Million